Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Tenaya Therapeutics, Inc. (TNYA) to participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. The company aims to develop therapies for heart disease.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen’s 44^th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:

TD Cowen 44^th Annual Health Conference
Format: Genetic Medicines Panel
Date: Tuesday, March 5
Time: 2:10 PM ET – 3:10 PM ET

Leerink Partners Global Biopharma Conference 2024
Format: Fireside Chat
Date: Tuesday, March 12
Time: 10:40 AM ET – 11:10 AM ET

The live presentations will be webcast and may be accessed from the Investors section of Tenaya’s website. A replay of the webcasts will be available on the Tenaya website for approximately 30 days following each conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com.

Contacts	Investors
Michelle Corral	Anne-Marie Fields
VP, Corporate Communications and Investor Relations	Stern Investor Relations
IR@tenayathera.com	Annemarie.fields@sternir.com

 

FAQ

When will Tenaya Therapeutics participate in TD Cowen's 44th Annual Health Care Conference?

Tenaya Therapeutics will participate in TD Cowen's 44th Annual Health Care Conference on Tuesday, March 5 from 2:10 PM ET to 3:10 PM ET.

What is the format of Tenaya Therapeutics' participation in Leerink Partners Global Biopharma Conference 2024?

Tenaya Therapeutics will participate in Leerink Partners Global Biopharma Conference 2024 in a Fireside Chat format on Tuesday, March 12 from 10:40 AM ET to 11:10 AM ET.

Where can the live presentations of Tenaya Therapeutics be accessed?

The live presentations of Tenaya Therapeutics can be accessed from the Investors section of the company's website.

Will there be a replay of the webcasts available?

Yes, a replay of the webcasts will be available on the Tenaya website for approximately 30 days following each conference.